Resveratrol reverses the effects of chronic unpredictable mild stress on behavior, serum corticosterone levels and BDNF expression in rats

Behavioural Brain Research

Volumn 264, Issue , 2014, Pages 9-16

  Liu, Dexiang ^a   Xie, Kai ^a   Yang, Xudong ^a   Gu, Jianhua ^a   Ge, Li ^b   Wang, Xueer ^a,c   Wang, Zhen ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TAISHAN MEDICAL UNIVERSITY   (China)

^c LUOYANG NORMAL UNIVERSITY   (China)

Author keywords

Brain derived neurotrophic factor (BDNF); Chronic unpredictable mild stress (CUMS); Hypothalamic pituitary adrenal (HPA); Resveratrol

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOSTERONE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DESIPRAMINE; MITOGEN ACTIVATED PROTEIN KINASE; RESVERATROL;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIORAL STRESS; BLOOD ANALYSIS; CHRONIC STRESS; CONTROLLED STUDY; CORTICOSTEROID BLOOD LEVEL; DEPRESSION; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFECT; FORCED SWIM TEST; HIPPOCAMPUS; MALE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; UPREGULATION;

BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF); CHRONIC UNPREDICTABLE MILD STRESS (CUMS); HYPOTHALAMIC-PITUITARY-ADRENAL (HPA); RESVERATROL;

ANIMALS; ANTIOXIDANTS; BODY WEIGHT; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORTICOSTERONE; CREB-BINDING PROTEIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; FOOD DEPRIVATION; FOOD PREFERENCES; GENE EXPRESSION REGULATION; MALE; RATS; RATS, WISTAR; STILBENES; STRESS, PSYCHOLOGICAL; SWIMMING; TIME FACTORS;

EID: 84896699510     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.01.039     Document Type: Article

References (51)

1. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl) 1997, 134(4):319-329.
2. Dinan T.G. Glucocorticoids and the genesis of depressive illness: a psychobiological model. Br J Psychiatry 1994, 164(3):365-371.
3. Tsigos C., Chrousos G.P. Physiology of the hypothalamic-pituitary-adrenal axis in health and dysregulation in psychiatric and autoimmune disorders. Endocrinol Metab Clin North Am 1994, 23(3):451-466.
4. Holsboer F., Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 1996, 17(2):187-205.
5. Mason B.L., Pariante C.M. The effects of antidepressants on the hypothalamic-pituitary-adrenal axis. Drug News Perspect 2006, 19(10):603-608.
6. Raone A., et al. Hypothalamus-pituitary-adrenal modifications consequent to chronic stress exposure in an experimental model of depression in rats. Neuroscience 2007, 146(4):1734-1742.
7. Xu Y., et al. Curcumin reverses the effects of chronic stress on behavior: the HPA axis, BDNF expression and phosphorylation of CREB. Brain Res 2006, 1122(1):56-64.
8. Castren E., Voikar V., Rantamaki T. Role of neurotrophic factors in depression. Curr Opin Pharmacol 2007, 7(1):18-21.
9. Karege F., et al. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005, 57(9):1068-1072.
10. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59(12):1116-1127.
11. Rantamaki T., et al. The effects of acute and long-term lithium treatments on trkB neurotrophin receptor activation in the mouse hippocampus and anterior cingulate cortex. Neuropharmacology 2006, 50(4):421-427.
12. Aydemir O., Deveci A., Taneli F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29(2):261-265.
13. Juan M.E., Alfaras I., Planas J.M. Colorectal cancer chemoprevention by trans-resveratrol. Pharmacol Res 2012, 65(6):584-591.
14. Zhang F., Liu J., Shi J.S. Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation. Eur J Pharmacol 2010, 636(1-3):1-7.
15. Orsu P., Murthy B.V., Akula A. Cerebroprotective potential of resveratrol through anti-oxidant and anti-inflammatory mechanisms in rats. J Neural Transm 2013, 120(8):1217-1223.
16. Tome-Carneiro J., et al. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol Res 2013, 72:69-82.
17. Zhuang H., et al. Potential mechanism by which resveratrol, a red wine constituent, protects neurons. Ann NY Acad Sci 2003, 993:276-286. discussion 287-288.
18. Jang J.H., Surh Y.J. Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radic Biol Med 2003, 34(8):1100-1110.
19. Sun A.Y., et al. Ethanol-induced cell death by lipid peroxidation in PC12 cells. Neurochem Res 1997, 22(10):1187-1192.
20. Tiwari V., Chopra K. Resveratrol abrogates alcohol-induced cognitive deficits by attenuating oxidative-nitrosative stress and inflammatory cascade in the adult rat brain. Neurochem Int 2013, 62(6):861-869.
21. Wang J., et al. Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. FASEB J 2006, 20(13):2313-2320.
22. Albani D., et al. The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. J Neurochem 2009, 110(5):1445-1456.
23. Xu Y., et al. Antidepressant-like effect of trans-resveratrol: involvement of serotonin and noradrenaline system. Eur Neuropsychopharmacol 2010, 20(6):405-413.
24. Yu Y., et al. Antidepressant-like effect of trans-resveratrol in chronic stress model: behavioral and neurochemical evidences. J Psychiatr Res 2013, 47(3):315-322.
25. Ducottet C., Griebel G., Belzung C. Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27(4):625-631.
26. Willner P., et al. Reduction of sucrose preference by chronic unpredictable mild stress: and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 1987, 93(3):358-364.
27. Russo E., et al. Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. Neuropharmacology 2013, 64:371-379.
28. Surget A., et al. Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal. Neuropsychopharmacology 2009, 34(6):1363-1380.
29. Vancassel S., et al. n-3 polyunsaturated fatty acid supplementation reverses stress-induced modifications on brain monoamine levels in mice. J Lipid Res 2008, 49(2):340-348.
30. Ibarguen-Vargas Y., et al. Multifaceted strain-specific effects in a mouse model of depression and of antidepressant reversal. Psychoneuroendocrinology 2008, 33(10):1357-1368.
31. Mutlu O., et al. Effects of neuronal and inducible NOS inhibitor 1-[2-(trifluoromethyl) phenyl] imidazole (TRIM) in unpredictable chronic mild stress procedure in mice. Pharmacol Biochem Behav 2009, 92(1):82-87.
32. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005, 52(2):90-110.
33. Tanti A., Belzung C. Open questions in current models of antidepressant action. Br J Pharmacol 2010, 159(6):1187-1200.
34. Zhu W.L., et al. Green tea polyphenols produce antidepressant-like effects in adult mice. Pharmacol Res 2012, 65(1):74-80.
35. Anacker C., et al. The glucocorticoid receptor: pivot of depression and of antidepressant treatment?. Psychoneuroendocrinology 2011, 36(3):415-425.
36. Yau J.L., et al. The antidepressant desipramine requires the ABCB1 (Mdr1)-type p-glycoprotein to upregulate the glucocorticoid receptor in mice. Neuropsychopharmacology 2007, 32(12):2520-2529.
37. Cunha A.B., et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 2006, 398(3):215-219.
38. Guilloux J.P., et al. Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. Mol Psychiatry 2012, 17(11):1130-1142.
39. Reus G.Z., et al. Imipramine reverses alterations in cytokines and BDNF levels induced by maternal deprivation in adult rats. Behav Brain Res 2013, 242:40-46.
40. Nibuya M., et al. Repeated stress increases catalytic TrkB mRNA in rat hippocampus. Neurosci Lett 1999, 267(2):81-84.
41. Chen B., et al. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001, 50(4):260-265.
42. Karege F., et al. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 2005, 136(1-2):29-37.
43. Shirayama Y., et al. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002, 22(8):3251-3261.
44. Thome J., et al. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci 2000, 20(11):4030-4036.
45. Nibuya M., Nestler E.J., Duman R.S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996, 16(7):2365-2372.
46. Huang E.J., Reichardt L.F. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001, 24:677-736.
47. Einat H., et al. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 2003, 23(19):7311-7316.
48. Ortiz J., et al. Extracellular signal-regulated protein kinases (ERKs) and ERK kinase (MEK) in brain: regional distribution and regulation by chronic morphine. J Neurosci 1995, 15(2):1285-1297.
49. Dwivedi Y., et al. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J Neurochem 2001, 77(3):916-928.
50. Chandran A., et al. Reduced phosphorylation of the mTOR signaling pathway components in the amygdala of rats exposed to chronic stress. Prog Neuropsychopharmacol Biol Psychiatry 2013, 40:240-245.
51. First M., et al. The effects of fluoxetine treatment in a chronic mild stress rat model on depression-related behavior: brain neurotrophins and ERK expression. J Mol Neurosci 2011, 45(2):246-255.